Kazakhstan vs Namibia: Average cost of multi drug-resistant tuberculosis treatment
Kazakhstan
3,398 constant 2022 US$
in 2023
Namibia
3,336 constant 2022 US$
in 2024
Kazakhstan rank
13th
Namibia rank
14th
Average cost of multi drug-resistant tuberculosis treatment over time
- Kazakhstan
- Namibia
How they compare
Kazakhstan currently reports 3,398 constant 2022 US$ against 3,336 constant 2022 US$ in Namibia, a difference of 62 constant 2022 US$.
The two have swapped places 3 times across 6 shared years of data; in 2017 it was Namibia ahead.
Kazakhstan ranks 13th and Namibia ranks 14th of 92 countries.
Across the 2 decades both report, Kazakhstan averaged higher in 1 and Namibia in 1.
Head to head by decade
| Decade | Kazakhstan | Namibia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,351 constant 2022 US$ | 5,099 constant 2022 US$ | 1,748 constant 2022 US$ | Namibia |
| 2020s | 2,932 constant 2022 US$ | 2,874 constant 2022 US$ | 58.5 constant 2022 US$ | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Kazakhstan or Namibia?
- Kazakhstan, at 3,398 constant 2022 US$ against 3,336 constant 2022 US$ in Namibia as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Kazakhstan and Namibia?
- 62 constant 2022 US$, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Namibia?
- 6 years are reported by both, from 2017 to 2023.
- How do Kazakhstan and Namibia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Kazakhstan ranks 13th and Namibia ranks 14th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.